🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

17 results for “BioXcel Therapeutics” Clear

  1. BXCL501

    BioXcel Therapeutics

    Agitation

    phase 3 small molecule completed

    4 trials

  2. BXCL501

    BioXcel Therapeutics

    Agitation,Psychomotor

    phase 3 small molecule completed

    1 trial

  3. Sublingual film containing Dexmedetomidine (BXCL501)

    BioXcel Therapeutics

    Agitation Associated With Bipolar Disorder

    phase 3 small molecule completed

    1 trial

  4. Sublingual film containing dexmedetomidine (BXCL501)

    BioXcel Therapeutics

    Agitation

    phase 3 small molecule completed

    1 trial

  5. BXCL501 Sublingual Film

    BioXcel Therapeutics

    Bipolar I Disorder

    phase 2 small molecule completed

    1 trial

  6. BXCL701

    BioXcel Therapeutics

    Metastatic Pancreatic Ductal Adenocarcinoma

    phase 2 small molecule active

    1 trial

  7. BXCL701 plus Pembrolizumab

    BioXcel Therapeutics

    Prostate Cancer

    phase 2 small molecule completed

    1 trial

  8. Dexmedetomidine

    BioXcel Therapeutics

    Opioid Withdrawal

    phase 2 small molecule completed

    1 trial

  9. Dexmedetomidine sublingual film

    BioXcel Therapeutics

    Delirium

    phase 2 small molecule terminated

    1 trial

  10. Sublingual film containing Dexmedetomidine

    BioXcel Therapeutics

    Agitation,Psychomotor

    phase 2 small molecule completed

    1 trial

  11. BXCL501 80 Micrograms

    BioXcel Therapeutics

    Schizophrenia

    phase 1 small molecule active

    1 trial

  12. Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 40µg

    BioXcel Therapeutics

    Alcohol Use Disorder (AUD)

    phase 1 small molecule active

    1 trial

  13. Placebo

    BioXcel Therapeutics

    Alcohol Use Disorder (AUD)

    phase 1 small molecule completed

    1 trial

  14. Sublingual film containing BXCL501 (Dexmedetomidine)

    BioXcel Therapeutics

    Agitation

    phase 1 small molecule completed

    1 trial

  15. Talabostat Mesylate

    BioXcel Therapeutics

    Cancer of Pancreas

    phase 1 small molecule terminated

    1 trial

  16. Dexmedetomidine

    BioXcel Therapeutics

    Schizophrenia Agitation

    approved small molecule active

    1 trial

  17. Sublingual film containing Igalmi

    BioXcel Therapeutics

    Bipolar Disorder

    approved small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources